IMUGENE LIMITED — Capital/Financing Update 2017

Mar 29, 2017

==> picture [168 x 75] intentionally omitted <==

$1.35 million Options Underwritten

March 30, 2017: Imugene Limited (ASX: IMU), an immuno-oncology company is pleased to announce that it has signed underwriting agreements with three existing institutional shareholders of IMU to underwrite up to $1.35 million (AUD) of options as part of the Company’s option plan which expires on 31[st] March 2017

The agreed issue price for any shares issued under the underwriting agreements is 1.5 cents per share (being the same as the exercise price of the options) and the total underwriting fee is approximately 3.8% of the total underwritten amount (approximately $51,000).

The underwriters are Platinum Investment Management Limited, Private Portfolio Managers and Celtic Capital, all existing and continued strong supporters of IMU over time.

IMU’s CEO, Leslie Chong said today “we are encouraged that such prominent shareholders have agreed to further increase their support and dedication by investing in Imugene. Funds raised from the options will be applied to continue our clinical development of HER-Vaxx and the preclinical work associated with the mimotope program.”

For further information please contact:

Imugene:

Leslie Chong Paul Hopper Chief Executive Officer Executive Chairman Tel: +61 458 040 433 Tel: +61 406 671 515

About Imugene (ASX:IMU)

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the Medical University of Vienna in Austria, the peptide vaccine is constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase I study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information please visit www.imugene.com Sign up to follow @ TeamImugene on Twitter at http://www.twitter.com/TeamImugene. To follow Imugene on Facebook visit www.facebook.com/imugene

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com